Trials / Recruiting
RecruitingNCT06539182
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Dizal Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | Daily oral dose of DZD8586 at 25 mg. |
| DRUG | DZD8586 | Daily oral dose of DZD8586 at 50 mg. |
| DRUG | DZD8586 | Daily oral dose of DZD8586 at 75 mg. |
Timeline
- Start date
- 2024-04-29
- Primary completion
- 2027-09-01
- Completion
- 2028-03-01
- First posted
- 2024-08-06
- Last updated
- 2025-12-01
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06539182. Inclusion in this directory is not an endorsement.